Keywords: PD-L1; Pembrolizumab; Pneumonitis; Autopsy; Lung cancer;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Bladder; Immune checkpoint inhibitors; Chemotherapy; Metastatic urothelial carcinoma; PD-L1; Response;
Keywords: irAE; immune related adverse event; ECOG PS; European cooperative oncology group performance status; n.s.; not significant; EGFR; epidermal growth factor receptor; ALK; anaplastic lymphoma kinase; PD-L1; programmed death-ligand 1; TKI; tyrosine-kinase inh
Keywords: Immune-checkpoint inhibitors; PD-L1; NSCLC; Meta-analysis;
Keywords: Lung cancer; Adenocarcinoma; Convex endobronchial ultrasound; PD-L1; Targeted therapy;
Keywords: TSCC; 4NQO mice model; Curcumin; PD-L1; Tregs; MDSCs;
Keywords: Immune privilege; CD47; CD274; Cytokine levels; Bone marrow; Stem cells; allo-HSCT; allogeneic hematopoietic stem cell transplantation; G-CSF; granulocyte - colony stimulating factor; PBSCs; peripheral blood stem cells; GVHD; graft-versus-host disease; cG
Keywords: PD-L1; PD-1; Immunohistochemistry; Sequencing; Mutational load; Primary lung; Metastasis;
Keywords: Non-small cell lung cancer (NSCLC); Adenocarcinoma; Cytology; Ancillary testing; Minimally invasive; PD-L1; Biomarker;
Keywords: EBV; Immunotherapy; PD-L1; Gastric cancer; Viruses; Biomarker;
Keywords: Biomarker; Brain tumor; Diagnosis; Meningioma; Molecular characterization; Prognosis; Recurrence; AKT1; v-Akt murine thymoma viral oncogene homolog 1; BAP1; BRCA1-associated protein 1; CDKN2A and B; Cyclin-dependent kinase inhibitor 2A and 2B; FAK; Focal
Keywords: Colorectal cancer; Mismatch repair deficiency; PD-1; PD-L1; Tumor immune microenvironment;
Keywords: Immune-checkpoint inhibitors; Metastatic urothelial carcinoma; Meta-analysis; Systematic review; PD-1; PD-L1;
Keywords: PD-L1; EGFR; Radiotherapy; Combination therapy; Glioma;
Keywords: Localized; Muscle-invasive; Non-muscle-invasive; Bladder cancer; Checkpoint inhibitor; PD-1; PD-L1; CTLA-4; Treatment; Therapy;
Keywords: PD-1; programed cell death-1; PD-L1; programmed cell death ligand 1; NSCLC; non-small-cell lung cancer; OS; overall survival; PFS; progression-free survival; ORR; objective response rate; irAEs; immune-related adverse events; RECIST; response evaluation c
Keywords: ARG-1; arginase 1; CCL-; CC motif chemokine ligand-; CXCL-; CX-C motif chemokine ligand-; CAF; cancer associated fibroblast; CO; carbon monoxide; CVB3; coxsackievirus B3; COX-2; cyclooxygenase-2; DC; dendritic cell; EAU; experimental autoimmune uveitis; E
Keywords: Nasopharyngeal carcinoma; Epstein-Barr virus; Immunotherapy; Cellular-based therapy; Vaccination; Head and neck cancer; DC; dendritic cell; NK; natural killer cell; CTL; cytotoxic T lymphocyte/cell; NPC; nasopharyngeal carcinoma; HLA; human leukocyte anti
Keywords: IDO1; PD-L1; Co-expression; Lung adenocarcinoma; Immunotherapy;
Keywords: 18F-FDG PET; PD-L1; Lung cancer; Adenocarcinoma; Immunohistochemistry; HIF-1α;
Keywords: AT; adipose tissue; BM; bone marrow; CsA; cyclosporine A; COX-2; cyclooxygenase-2; DEX; dexamethasone; DMEM; Dulbeccós modified Eaglés medium; DMSO; dimethyl sulfoxide; ELISA; enzyme-linked immunosorbent assay; FasL; Fas ligand; HGF; hepatocyte growth f
Keywords: BG-DCs; dendritic cells matured with oncolysate-pre-loaded bacterial ghosts plus interferon gamma; BG; bacterial ghost; CFSE; carboxyfluorescein succinimidyl ester; DAMP; damage-associated molecular pattern; DC; dendritic cell; ELISPOT; enzyme-linked immu
Keywords: biomarker; cancer outcome; cutaneous adverse event; cutaneous toxicity; oncodermatology; prognostic marker; survival; HFS; hand foot syndrome; HFSR; hand-foot skin reaction; HR; hazard ratio; irAE; immune-related adverse effect; NSCLC; non-small cell
Keywords: ADAM; a disintegrin and metalloproteinase; APP; amyloid precursor protein; APC; antigen presenting cell; Aβ; β-amyloid; B7-H1; B7-homolog 1; CARD; caspase activation and recruitment domain; CCR; C-C chemokine receptor; CIM; C-protein induced myositis; C
Keywords: AdV; adenovirus; ATP; adenosine triphosphate; APC; antigen presenting cell; CTLA-4; cytotoxic T lymphocyte antigen 4; CTL; cytotoxic T lymphocyte; CXCL/CCL; C-X-C motif ligands; DAMPs; damage-associated molecular pattern molecules; DC; dendritic cell; GIT
Keywords: HPV; human papilloma virus; CC; cervical cancer; EC; endometrial cancer; CIN; cervical intraepithelial neoplasia; VIN; vulvar intraepithelial neoplasia; VaIN; vaginal intraepithelial neoplasia; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; PD-1; pr
Keywords: urinary bladder neoplasms; carcinoma; programmed cell death 1 receptor; immunotherapy; APC; antigen-presenting cell; BCG; bacillus Calmette-Guérin; CD; cluster of differentiation; CR; complete response; CTLA-4; cytotoxic T-lymphocyte-associated antigen-4
Keywords: Immune-related adverse event; PD1; PD-L1; Complications; Imaging;
Keywords: EORTC; European Organization for Research and Treatment of Cancer; NCI-MATCH; National Cancer Institute- Molecular Analysis for Therapy Choice; RECIST; Response Evaluation Criteria In Solid Tumors; SITC; Society for ImmunoTherapy of Cancer; SPECTA; Screen
Keywords: PD-1; PD-L1; Immunotherapy; Checkpoint inhibitors; Biomarkers; Non-small cell lung cancer; Tumor mutational burden; Microbiome;
Keywords: AKAP4; A-kinase anchor protein 4; CAGE; cancer-associated gene protein; CTAs; cancer - testis antigens; CT47A; cancer-testis antigen family 47; member A; C12orf54, chromosome 12 open reading frame 54; LIN28B; lin-28 homolog B; MAD; median absolute deviati
Keywords: ARID; Age Related Immune Differences; CD40L; CD40 ligand; CTLA-4; cytotoxic T lymphocyte antigen-4; IL; interleukin; Lag3; lymphocyte activation gene 3; MDSC; myeloid derived suppressor cell; MHC; major histocompatibility complex; mTOR; mammalian target o
Keywords: 5-FU; 5-fluoro-uracil; AAV; adeno-associated virus; ADAM; ADAM metallopeptidase domain; ADCC; antibody-dependent cell-mediated cytotoxicity; CCL; chemokine (C-C motif) ligand; CD; cluster of differentiation; CTLA-4; cytotoxic T-lymphocyte-associated ant
Keywords: CT; computed tomography; C/T; consolidation/tumor ratio; EGFR; epidermal growth factor receptor; NSCLC; non-small cell lung cancer; OS; overall survival; pD-L1; programmed cell death-1 ligand; PET; positron emission tomography; RFS; recurrence-free surviv
Keywords: 5FU; 5-fluorouracil; 95%CI; 95% confidence interval; AA; amino acid; AFP; alpha fetoprotein; AML; actue myeloid leukemia; Ang2; angiopoietin 2; ATP; adenosine triphosphate; BCLC; Barcelona-Clinic Liver Cancer classification; BSC; best supportive care; CAP
Keywords: Urinary cell mRNA profiling; Polymerase chain reaction; Rejection; Tolerance; Kidney transplantation; mRNA; messenger RNA; RT-QPCR; real-time quantitative PCR; ACR; acute cellular rejection; ROC; receiver-operating-characteristic; PI-9; proteinase inhibit
Keywords: Clinical outcome; Radiofrequency ablation; Hepatocellular carcinoma; Alpha-fetoprotein; microRNAs; PD-L1; Nivolumab; Tremelimumab; Immunotherapy; Circulating miRNAs;
Keywords: Head and neck cancer; Nasopharynx cancer; Immunotherapy; PD-L1; Immune checkpoint; HPV; EBV;
Keywords: AE; adverse event; ALK; anaplastic lymphoma kinase; aNSCLC; advanced non-small cell lung cancer; DRG; diagnosis-related group; EGFR; epidermal growth factor receptor; GLM; generalized linear model; HMO; health maintenance organization; HR; hazard ratio; I
Keywords: VEGF; vascular endothelial growth factor; TNF-α; tumor-necrosis-factor a; PDGFB; platelet-derived growth factor B; PIGF; placental growth factor; Sema3A; Semaphorin3A; TAM; Tumor-associated macrophages; TEM; Tie2-expressing macrophages; TAN; Tumor-associ
Keywords: EGFR-TKI; NSCLC; PD-L1; Smoking; Tumor-infiltrating lymphocytes;
Keywords: malignant pleural mesothelioma; PD-L1; gene expression profile; NanoString technology;
Keywords: BATF; basic leucine zipper transcription factor; BM; bone marrow; Bregs; regulatory B cells; BTLA; B and T lymphocyte attenuator; CFSE; carboxyfluorescein succinimidyl ester; CML; cell mediated lympholysis; CNI; calcineurin inhibitor; CPM; counts per minu
Keywords: Immune-oncology; Molecular testing; Non-small-cell lung cancer; Pathology; PD-L1; Targeted treatment;
Keywords: ARID; Age Related Immune Dysfunction; BCG; Bacille Calmette-Guérin; CAR; chimeric antigen receptor; CDMRP; Congressionally Directed Medical Research Program; CD40L; CD40 ligand; CpG; poly-(cysteine 5â² to guanine); CRISPR; clustered regularly interspace
Keywords: Pancreatic cancer; Immunotherapy; Tumor associated antigen; PD-L1;
Keywords: Dendritic cells; Immunogenicity; Glioblastoma; Nano-DOX; Drug delivery; Immunogenic cell death; ATP; adenosine triphosphate; BBB; blood-brain barrier; BCA; bicinchoninic acid; 5-(N-dodecanoyl)aminofluorescein; C11-fluor; DC; dendritic cells; MÏ; macropha
Keywords: mast cells; degranulation; Mas-related G protein-coupled receptor X2; IL-33; adhesion G protein-coupled receptor E2; tryptase; allergy; mastocytosis; ADGRE2; Adhesion G protein-coupled receptor E2; CPA3; Carboxypeptidase 3; CTMC; Connective tissue m
Keywords: CTC; circulating tumor cell; CTL; cytotoxic T lymphocyte; DC; dendritic cell; DDR; DNA damage response; DSB; double-stand break; dsDNA; double-stranded DNA; FDA; Food and Drug Administration; ICB; immune checkpoint blocker; IFN; interferon; IHC; immunohis
Keywords: GCA; giant cell arteritis; IL; interleukin; MHC-1; major histocompatibility complex class I; MMP; matrix metalloproteinase; PD-L1; programmed death ligand-1; TA; temporal artery; VZV; varicella zoster virus; Varicella zoster virus; Vasculopathy; Inflammat